Agios Pharmaceuticals Inc (NAS:AGIO)
$ 59.005 -0.015 (-0.03%) Market Cap: 3.37 Bil Enterprise Value: 2.41 Bil PE Ratio: 5.19 PB Ratio: 2.07 GF Score: 37/100

Agios Pharmaceuticals Inc Investor Relations Event Transcript

Dec 21, 2020 / 01:00PM GMT
Release Date Price: $42.62 (+28.33%)
Holly Manning
Agios Pharmaceuticals, Inc. - Director of IR

(technical difficulty) (Operator Instructions) And with that, Jackie, I will turn it over to you.

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Thank you, Holly. Good morning, everybody. Thank you for joining us this morning, as we're very excited to talk to you about how we're taking Agios into a future full of potential, with a lot of opportunities ahead of us as we reimagine our future. We've also this morning announced a transaction that will enable that future, and I'll talk a little bit more about that transaction as well.

Delivering excellence is something that has always been at the core of what we do at Agios, and we've done that over the course of our 12 years of existence, and we intend to continue to do that for a very, very long time as we try to bring the full potential of our science to the patients that we want to serve. Part of delivering excellence also includes being willing to evolve your strategy and your approach as the landscape around new changes

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot